[In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples]
- PMID: 17682710
[In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples]
Abstract
In recent years, the incidence of Candida albicans infections tends to decrease, at least in some centers other Candida species have emerged as opportunistic pathogens. Among non-albicans Candida species, C. glabrata is one of the most frequently isolated species. In this study, the in vitro activities of amphotericin B, itraconazole and fluconazole were tested against 134 clinical C. glabrata strains. The isolation and identification of the isolates were done by standard mycological methods. Microbroth susceptibility tests were done in accordance with CLSI microdilution method (M27A-2). MICs were read at both 24 and 48 hours. At 24 h, MIC range, MIC50 and MIC90 values for amphotericin B were 0.5-4 micorg/ml, 2 microg/ml and 4 microg/ml, respectively. At 48 h, MIC range, MIC50 and MIC90 values for amphotericin B were 2-4 microg/ml, 4 microg/ml and 4 microg/ml respectively. At 24 h, 97% of the isolates were susceptible (S) and 3% were dose-dependent susceptible (S-DD) to fluconazole. None of the isolates were resistant (R) to fluconazole at this time point. At 48 h, 94% of the isolates were S, 5.2% were S-DD and 0.8% were R to fluconazole. At 24 h, 20.9% of the isolates were S, 73.1% were S-DD and 6% were R to itraconazole. At 48 h, 0.8% of the isolates were S, 62.7% were S-DD and 36.5% were R to itraconazole. These results suggest that although C.glabrata strains that were isolated in our hospital were rarely resistant to fluconazole, resistance rate to itraconazole is relatively high. Most of the isolates that are resistant to itraconazole remain susceptible to fluconazole.
Similar articles
-
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13. Int J Antimicrob Agents. 2008. PMID: 18790613
-
[Molecular epidemiology and antifungal susceptibility of Candida species isolated from urine samples of patients in intensive care unit].Mikrobiyol Bul. 2011 Jan;45(1):137-49. Mikrobiyol Bul. 2011. PMID: 21341168 Turkish.
-
In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).Mycoses. 2004 Jun;47(5-6):177-83. doi: 10.1111/j.1439-0507.2004.00971.x. Mycoses. 2004. PMID: 15189180
-
The role of antifungal susceptibility testing in the therapy of candidiasis.Diagn Microbiol Infect Dis. 2004 Mar;48(3):153-60. doi: 10.1016/j.diagmicrobio.2003.10.003. Diagn Microbiol Infect Dis. 2004. PMID: 15023422 Review.
-
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.Clin Infect Dis. 1997 Feb;24(2):235-47. doi: 10.1093/clinids/24.2.235. Clin Infect Dis. 1997. PMID: 9114154 Review.
Cited by
-
Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.Mycopathologia. 2011 Sep;172(3):187-99. doi: 10.1007/s11046-011-9413-y. Epub 2011 Mar 20. Mycopathologia. 2011. PMID: 21424603
MeSH terms
Substances
LinkOut - more resources
Medical